



August 29, 2024

Lorraine Mazzeo
Staff Regulatory Affairs Specialist
47900 Bayside Parkway
Fremont, California 94538

Re: K242243
Trade/Device Name: Target Detachable Coils
Regulation Number: 21 CFR 882.5950
Regulation Name: Neurovascular embolization device
Regulatory Class: Class II
Product Code: HCG, KRD
Dated: July 30, 2024
Received: July 31, 2024

Dear Lorraine Mazzeo:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Sara S. Thompson -S

Sara S. Thompson, D.V.M.

Assistant Director

DHT5A: Division of Neurosurgical,

Neurointerventional, and

Neurodiagnostic Devices

OHT5: Office of Neurological and

Physical Medicine Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

Indications for Use

Submission Number (if known)

K242243

Device Name

Target Detachable Coils

Indications for Use (Describe)

Target Detachable Coils are intended to endovascularly obstruct or occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.

Target Detachable Coils are indicated for endovascular embolization of:

- Intracranial aneurysms
- Other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae
- Arterial and venous embolizations in the peripheral vasculature

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Stryker Neurovascular
Premarket Notification, Special 510(k)
Target Detachable Coils

Date Prepared: July 30, 2024

Submitter: Stryker Neurovascular
47900 Bayside Parkway
Fremont, CA 94538
Facility Registration #300853977

Contact: Lorraine Mazzeo
Staff Regulatory Affairs Specialist
Tel (510) 413-2676
E-mail: lorraine.mazzeo@stryker.com

Device Trade Name: Target Detachable Coils

Classification Name: Target Detachable Coils are vascular and neurovascular embolization devices under 21 CFR 870.3300 (KRD) and 21 CFR 882.5950 (HCG), respectively, and are Class II devices (special controls).

The special control for the devices is FDA's guidance document, *Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices* (issued 29 Dec 2004).

Legally Marketed Predicate Device:

Predicate Devices
K153658 (Cleared 19-May-2016)
K161429 (Cleared 22-June-2016)
K222533 (Cleared 14-Dec-2022)

Stryker Neurovascular

Premarket Notification, Special 510(k)

Target Detachable Coils

DEVICE DESCRIPTION

Stryker Neurovascular **Target Detachable Coils** are comprised of the following coil types:

Target 360 Nano	Target Helical Nano	Target XL 360 Soft
Target 360 Ultra	Target Helical Ultra	Target XL 360 Standard
Target 360 Soft	Target 3D	Target XL Helical
Target 360 Standard	Target XXL 360	Target Tetra

Please note that all Target Detachable Coils referenced in this submission are considered the subject device.

All Target Coils are stretch resistant coils. Target Coils incorporate a length of monofilament stretch resistant fiber or in the case of the Target Tetra, multi-strand material through the center of the coil designed to help resist stretching. Target Coils are designed for use with the Stryker Neurovascular InZone® Detachment System (sold separately).

Each Target Coil type consists of a platinum-tungsten alloy coil attached to a stainless-steel delivery wire.

The Stryker Neurovascular InZone® Detachment System is intended for use with all Stryker Neurovascular Detachable Coils in the embolization of intracranial aneurysms and other vascular malformations of the neuro and peripheral vasculature.

COMPARISON TO THE PREDICATE DEVICE: TARGET DETACHABLE COILS

This 510(k) requests clearance for the consolidation of three separate Target Instructions for Use (IFUs) into a single shared IFU and consolidates two separate Target Patient Information Leaflet (PIL) with Patient Information Card (PIC), making it a single PIL with PIC for all Target Detachable Coils, in addition to other changes made since the last 510(k) clearance resulting in a cumulative assessment that a new 510(k) is required. The subject devices utilize the same design and materials of existing Target Coils, and the same manufacturing, packaging and sterilization processes.

The modified Stryker Neurovascular Target Detachable Coils have the same intended use/indications for use as the predicate Target Detachable Coils. The modifications do not alter the intended use, indications for use, or the fundamental scientific technology of the Predicate Devices. A comparison of the Subject Device with the Predicate Devices is summarized in **Table 1** below.

Stryker Neurovascular
Premarket Notification, Special 510(k)
Target Detachable Coils

Table 1. Substantial Equivalence Comparison

Characteristic	Predicate Devices K153658/K161429/K222533	Subject Device
Manufacturer	Stryker	Same
Trade Name	Target Detachable Coils	Same
Device Type	Vascular Embolization Device; Neurovascular Embolization Device	Same
Classification Regulation (21 CFR)	870.3300, Class 2 882.5950, Class 2	Same
Product Code:	KRD, HCG	Same
Intended Use/Indication for Use	Target Detachable Coils are intended to endovascularly obstruct or occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels. Target Detachable Coils are indicated for endovascular embolization of: • Intracranial aneurysms • Other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae • Arterial and venous embolizations in the peripheral vasculature	Same
How Supplied	Single Use/Sterile	Same
Method of Sterilization	Ethylene Oxide (EtO) Gas	Same
Coil Material	Platinum/Tungsten alloy	Same
Delivery Wire Material	Stainless steel	Same
Features		
Secondary Coil Outer Diameter	1 mm – 24 mm	Same
Coil Length	1 cm – 50 cm	Same
Coil Secondary Shape Types	Helical, 360, 3D, Tetrahedral	Same
Power Supply Compatibility	InZone® Detachment System	Same
Packaging Configuration and Materials	Pouch: Tyvek/Film pouch Carton: Chipboard carton Dispenser coil (Hoop): HDPE tubing and clips	Same

Stryker Neurovascular
Premarket Notification, Special 510(k)
Target Detachable Coils

ACCESSORIES

Target Detachable Coils are not packaged with any accessories.

INTENDED USE / INDICATION FOR USE:

Intended Use:

Target Detachable Coils are intended to endovascularly obstruct or occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.

Indication for Use:

Target Detachable Coils are indicated for endovascular embolization of:

- Intracranial aneurysms
- Other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae
- Arterial and venous embolizations in the peripheral vasculature

CONCLUSION

Because the subject modifications do not alter the intended use or indications for use of the predicate devices, or the fundamental scientific technology of the predicate devices; and because the risk assessment of the modifications raise no new questions of safety and effectiveness, Stryker Neurovascular has determined the modified Target Detachable Coils to be substantially equivalent to the predicate device.